Skip to content

Novavax NVAX Free cash flow margin

Free cash flow margin at other companies

Moderna logo
ModernaMRNA
-132.4%
Roivant Sciences logo
Roivant SciencesROIV
-9,183.5%-17,093pp
Merck & Co. logo
Merck & Co.MRK
21.5%-5.2pp
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-428.4%-214pp
ALN
Alnylam PharmaceuticalsALNY
15%+12.7pp
Gilead Sciences logo
Gilead SciencesGILD
34.4%+0.1pp

Other financials

Income statement

See full
Revenue$139.5M-79.1%
Gross profit$108.8M-83.3%
Operating income-$15.4M-103%
Net income-$9.5M-102%
EPS (diluted)-$0.06-102%

Balance sheet

See full
Cash & equivalents$228.4M-13.3%
Total debt$295.1M+404%
Total equity-$144.8M-91.4%
Total assets$1.0B-19.3%

Cash flow

See full
Operating cash flow-$32.4M+82.5%
CapEx$1.3M-20.4%
Free cash flow-$33.7M+82.0%

Valuation

See full
Market cap$1.46B+41.0%
Enterprise value$1.53B+83.6%
P/S2.5×+1.6×

Profitability

See full
Gross margin85%-2.5pp
Operating margin-13.1%-45.9pp
Net margin-14.7%-52.9pp

Returns & leverage

See full
Return on equity-238.6%
Debt / equity1.5×
Current ratio2.5×+0.4×

Where this comes from

Calculated from Novavax’s reported figures.

Based on trailing twelve months.

The official record: Novavax’s 10-Q, filed August 6, 2025, on SEC EDGAR. View the filing →

Ask your AI about Novavax's free cash flow margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Novavax's free cash flow margin?
Novavax (NVAX) reported free cash flow margin of -58.9% in Q2 2025.
How has Novavax's free cash flow margin changed year-over-year?
Novavax's free cash flow margin decreased by 2490.1% year-over-year, from -2.3% to -58.9%.
What is the long-term trend for Novavax's free cash flow margin?
Over 3 years (2020 to 2024), Novavax's free cash flow margin has grown at a -10.4% compound annual growth rate (CAGR), from -20.4% to -14.7%.
What does free cash flow margin mean?
Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.